Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346775 · ClinicalTrials.gov registry record · Phase 3
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
NCT00346775 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 97 participants.
The verdict
NCT00346775, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
Study Summary
The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.
Interventions
- DRUG Beclomethasone dipropionate
- DRUG Flunisolide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2006-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346775
The ClinicalTrials.gov registry entry for NCT00346775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Beclomethasone dipropionate is the first listed.
NCT00346775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346775 about?
NCT00346775 is a clinical study titled "Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)". The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among...
What is the current status of trial NCT00346775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2006-05-01. Estimated completion is 2006-06-29.
What interventions are being tested in trial NCT00346775?
The interventions under investigation include: Beclomethasone dipropionate (DRUG), Flunisolide (DRUG).
Who is sponsoring clinical trial NCT00346775?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.